Ardelyx (ARDX) Leerink Global Healthcare Conference 2026 summary

Commercial performance and growth outlook

• IBSRELA achieved 73% growth in 2025, with 2026 guidance set at $410–$430 million, representing about 50% growth and targeting over $1 billion by 2029, requiring a 38% CAGR.

• XPHOZAH's Non-Medicare business grew 41% in 2025, with total dispenses up 9%, and 2026 guidance projects 5–10% growth.

• Commercial strategy focuses on expanding and optimizing the sales force, enhancing field reimbursement teams, and leveraging a specialized pharmacy network to drive both new prescriptions and refills.

• Primary care, gastroenterologists, and advanced practice providers collectively drive about 50% of IBSRELA prescriptions, with ongoing efforts to deepen engagement and expand reach.

• Top-line revenue is growing faster than expenses, with cash generation supporting ongoing investments and future aspirations.

Pipeline development and clinical programs

• The EXCEL Phase III trial for CIC is powered at 95% to detect a 14% difference versus placebo, targeting enrollment completion by year-end and data readout in the second half of next year.

• CIC represents a market two to three times larger than IBS-C, with plans to expand the sales force and leverage synergies between indications.

• The next-generation NHE3 inhibitor program (531) aims for IND submission by year-end, with preclinical studies exploring broader therapeutic opportunities.

• New tenapanor formulation patents extend IP protection, with composition of matter coverage to 2033 and method of use to 2034, providing valuable barriers to generic entry.

Strategic investments and financial management

• 2026 OpEx is guided at $520 million, with a steady investment pace across sales, marketing, and R&D, particularly for CIC and 531 programs.

• R&D is expected to rise as a percentage of OpEx, reflecting increased pipeline activity.

• ROI is closely tracked for all programs, with field sales teams delivering the highest returns.

• The company expects to fund most initiatives with internally generated cash through 2030.